Industry NewsDrug discovery > Clinical Development
Maze Therapeutics announces Phase 1 trial initiation evaluating MZE001 as a potential oral treatment for Pompe Disease
New therapeutic is designed to inhibit the buildup of glycogen in patients with Pompe Disease